Financial Survey: AzurRx BioPharma (AZRX) & Its Competitors

AzurRx BioPharma (NASDAQ: AZRX) is one of 104 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare AzurRx BioPharma to similar businesses based on the strength of its dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for AzurRx BioPharma and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AzurRx BioPharma 0 0 1 0 3.00
AzurRx BioPharma Competitors 905 3899 6912 184 2.54

AzurRx BioPharma presently has a consensus target price of $8.00, indicating a potential upside of 128.57%. As a group, “Pharmaceuticals” companies have a potential upside of 18.93%. Given AzurRx BioPharma’s stronger consensus rating and higher probable upside, analysts plainly believe AzurRx BioPharma is more favorable than its peers.


This table compares AzurRx BioPharma and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AzurRx BioPharma N/A -470.85% -205.40%
AzurRx BioPharma Competitors -2,433.24% -68.97% -8.86%

Insider & Institutional Ownership

8.2% of AzurRx BioPharma shares are held by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 9.1% of AzurRx BioPharma shares are held by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares AzurRx BioPharma and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
AzurRx BioPharma N/A -$14.59 million -2.43
AzurRx BioPharma Competitors $8.31 billion $1.11 billion 139.15

AzurRx BioPharma’s peers have higher revenue and earnings than AzurRx BioPharma. AzurRx BioPharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


AzurRx BioPharma peers beat AzurRx BioPharma on 8 of the 12 factors compared.

AzurRx BioPharma Company Profile

AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with's FREE daily email newsletter.

Leave a Reply